Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 193)
Posted On: 02/02/2018 6:42:11 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer
- Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™
- Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners
- The agreement is expected to generate new cannabis-based edible products for domestic and international markets
On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://nnw.fm/9DgLc). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years of experience in the production of high-quality chocolate and confectionery products for several prominent domestic and international chocolate brands. Cannfections is a pending entrant to the Licensed Producer program for cannabis-infused products.
Under this agreement, Lexaria is able to offer other licensee partners the use of Cannfections’ formulation and manufacturing expertise for the production of cannabis-infused chocolates and gummies, powered by Lexaria’s patented DehydraTECH™ delivery technology. This is expected to generate new product entries for Canadian cannabis edibles for the domestic market, as well as the growing number of international markets.
DehydraTECH™ is a patented, cost-effective and proven delivery technology that enhances the taste, smell, speed of action, bioabsorption and bioavailability of beneficial compounds in ingestible products. This technology has been awarded patents in the United States and Australia, and it has patents pending in 44 other countries. Lexaria is the only company in the world with a patent for the oral delivery of all non-psychoactive cannabinoids, such as cannabidiol (CBD). Lexaria’s patents involve the use of its proprietary technology for oral delivery of an extensive range of lipophilic active compounds, including cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), vitamins and nicotine.
Lexaria’s proprietary DehydraTECH™ technology masks recognition of the flavor and odor of compounds by oral and olfactory receptors. It enables manufacturers to create healthier, low-sugar products by eliminating the sugars and sweeteners traditionally used in product formulations to mask bitter tastes and unpleasant smells. This technology also increases the bioabsorption of cannabinoids and other active ingredients by up to 10 times. While other delivery technologies typically take between 60 and 120 minutes to take effect, DeydraTECH™ has been proven to register the onset of effects within 15 to 20 minutes.
Consumers benefit significantly from the enhanced taste of edibles and the reduced time to effect. As a disruptor in the growing cannabis market, Lexaria’s technology can either reduce the cannabinoid per serving unit cost, or deliver stronger effects where serving levels are regulated. The company’s technology can be applied to the manufacture of diverse product dosage forms, including foods, emulsions, liquids, tablets and capsules. Lexaria has produced a range of products for testing, demonstration and sales. These include CBD tablets, protein energy bars, exotic teas and TurboCBD, a high-absorption hemp oil capsule containing ginseng and ginkgo.
Lexaria has signed several royalty agreements for the use of its proprietary delivery technology with companies in Canada and the United States. Its latest venture with Cannfections is another step in the company’s ongoing pursuit of strategic partnerships with leading global companies to expand adoption of its innovative technology and deliver increased value for shareholders.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™
- Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners
- The agreement is expected to generate new cannabis-based edible products for domestic and international markets
On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://nnw.fm/9DgLc). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years of experience in the production of high-quality chocolate and confectionery products for several prominent domestic and international chocolate brands. Cannfections is a pending entrant to the Licensed Producer program for cannabis-infused products.
Under this agreement, Lexaria is able to offer other licensee partners the use of Cannfections’ formulation and manufacturing expertise for the production of cannabis-infused chocolates and gummies, powered by Lexaria’s patented DehydraTECH™ delivery technology. This is expected to generate new product entries for Canadian cannabis edibles for the domestic market, as well as the growing number of international markets.
DehydraTECH™ is a patented, cost-effective and proven delivery technology that enhances the taste, smell, speed of action, bioabsorption and bioavailability of beneficial compounds in ingestible products. This technology has been awarded patents in the United States and Australia, and it has patents pending in 44 other countries. Lexaria is the only company in the world with a patent for the oral delivery of all non-psychoactive cannabinoids, such as cannabidiol (CBD). Lexaria’s patents involve the use of its proprietary technology for oral delivery of an extensive range of lipophilic active compounds, including cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), vitamins and nicotine.
Lexaria’s proprietary DehydraTECH™ technology masks recognition of the flavor and odor of compounds by oral and olfactory receptors. It enables manufacturers to create healthier, low-sugar products by eliminating the sugars and sweeteners traditionally used in product formulations to mask bitter tastes and unpleasant smells. This technology also increases the bioabsorption of cannabinoids and other active ingredients by up to 10 times. While other delivery technologies typically take between 60 and 120 minutes to take effect, DeydraTECH™ has been proven to register the onset of effects within 15 to 20 minutes.
Consumers benefit significantly from the enhanced taste of edibles and the reduced time to effect. As a disruptor in the growing cannabis market, Lexaria’s technology can either reduce the cannabinoid per serving unit cost, or deliver stronger effects where serving levels are regulated. The company’s technology can be applied to the manufacture of diverse product dosage forms, including foods, emulsions, liquids, tablets and capsules. Lexaria has produced a range of products for testing, demonstration and sales. These include CBD tablets, protein energy bars, exotic teas and TurboCBD, a high-absorption hemp oil capsule containing ginseng and ginkgo.
Lexaria has signed several royalty agreements for the use of its proprietary delivery technology with companies in Canada and the United States. Its latest venture with Cannfections is another step in the company’s ongoing pursuit of strategic partnerships with leading global companies to expand adoption of its innovative technology and deliver increased value for shareholders.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼